Corbus Pharmaceuticals Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Corbus Pharmaceuticals Holdings has been growing earnings at an average annual rate of 18.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 85.2% per year.
Anahtar bilgiler
18.5%
Kazanç büyüme oranı
35.9%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | -85.2% |
Özkaynak getirisi | -27.9% |
Net Marj | n/a |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Jan 30Corbus Pharmaceuticals GAAP EPS of -$0.11
Aug 09Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?
Nov 19Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely
Jun 12Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?
May 14What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?
Mar 11Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?
Feb 04Corbus Pharmaceuticals: Down But Not Out
Jan 29Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
Jan 09Corbus's lenabasum shows benefit in autoimmune disorder
Nov 09Gelir ve Gider Dağılımı
Corbus Pharmaceuticals Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 0 | -35 | 14 | 0 |
31 Mar 24 | 0 | -34 | 14 | 0 |
31 Dec 23 | 0 | -45 | 14 | 0 |
30 Sep 23 | 0 | -47 | 15 | 0 |
30 Jun 23 | 0 | -46 | 16 | 0 |
31 Mar 23 | 0 | -51 | 17 | 0 |
31 Dec 22 | 0 | -42 | 19 | 0 |
30 Sep 22 | 0 | -42 | 18 | 0 |
30 Jun 22 | 0 | -35 | 20 | 0 |
31 Mar 22 | 0 | -39 | 20 | 0 |
31 Dec 21 | 1 | -46 | 20 | 0 |
30 Sep 21 | 2 | -44 | 22 | 0 |
30 Jun 21 | 3 | -77 | 24 | 0 |
31 Mar 21 | 3 | -98 | 26 | 0 |
31 Dec 20 | 4 | -111 | 28 | 0 |
30 Sep 20 | 6 | -129 | 29 | 0 |
30 Jun 20 | 7 | -115 | 27 | 0 |
31 Mar 20 | 36 | -75 | 25 | 0 |
31 Dec 19 | 36 | -71 | 24 | 0 |
30 Sep 19 | 35 | -62 | 21 | 0 |
30 Jun 19 | 34 | -56 | 19 | 0 |
31 Mar 19 | 6 | -70 | 17 | 0 |
31 Dec 18 | 5 | -56 | 13 | 0 |
30 Sep 18 | 3 | -49 | 12 | 0 |
30 Jun 18 | 3 | -41 | 11 | 0 |
31 Mar 18 | 2 | -37 | 10 | 0 |
31 Dec 17 | 2 | -32 | 9 | 0 |
30 Sep 17 | 3 | -29 | 9 | 0 |
30 Jun 17 | 3 | -28 | 9 | 0 |
31 Mar 17 | 3 | -25 | 8 | 0 |
31 Dec 16 | 2 | -20 | 6 | 0 |
30 Sep 16 | 2 | -15 | 5 | 0 |
30 Jun 16 | 1 | -12 | 4 | 0 |
31 Mar 16 | 1 | -10 | 4 | 0 |
31 Dec 15 | 1 | -9 | 4 | 0 |
30 Sep 15 | 0 | -8 | 3 | 0 |
30 Jun 15 | 0 | -6 | 3 | 0 |
31 Mar 15 | 0 | -4 | 2 | 0 |
31 Dec 14 | 0 | -3 | 1 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Kaliteli Kazançlar: CRBP is currently unprofitable.
Büyüyen Kar Marjı: CRBP is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: CRBP is unprofitable, but has reduced losses over the past 5 years at a rate of 18.5% per year.
Büyüme Hızlandırma: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: CRBP has a negative Return on Equity (-27.86%), as it is currently unprofitable.